DAPACORD

Description

Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor indicated for managing diabetes mellitus type 2. Dapagliflozin was approved by the FDA on Jan 08, 2014.

Indication:

Dapagliflozin is indicated to improve glycaemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.

Dosage:

The recommended dose is 10 mg once daily for best glycemic control. Warning & Precautions:

Volume depletion: Before initiating dapagliflozin, assess volume status and renal function in the elderly, patients with renal impairment or low systolic blood pressure, and in patients on diuretics. Monitor for signs and symptoms during therapy. Hypoglycaemia: Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycaemia when used in combination with dapagliflozin.

Drug Interactions :

Dapagliflozin may add to the diuretic effect of thiazide and loop diuretics and may increase the risk of dehydration and hypotension. Lower Dose of insulin or an insulin secretagogues such as sulphonylureas, may be required to reduce the risk of hypoglycaemia when used in combination with dapagliflozin in patients with type 2 diabetes mellitus.

Side Effects:

Most common side effect is Hypoglycaemia (when used with Sulfonylurea or insulin).Adverse effects include Vulvovaginitis, balanitis and related genital infections, Urinary tract infection, Dizziness, Rash, Back pain, Dysuria, Polyuria.

How Supplied :

Each film coated tablet contains Dapagliflozin 10mg

Storage :

Store in cool & dry places and protect from light & Moisture. Store in a safe place out of reach of children.